256 related articles for article (PubMed ID: 24101228)
1. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors.
Gieffers C; Kluge M; Merz C; Sykora J; Thiemann M; Schaal R; Fischer C; Branschädel M; Abhari BA; Hohenberger P; Fulda S; Fricke H; Hill O
Mol Cancer Ther; 2013 Dec; 12(12):2735-47. PubMed ID: 24101228
[TBL] [Abstract][Full Text] [Related]
2. Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors.
Phillips DC; Buchanan FG; Cheng D; Solomon LR; Xiao Y; Xue J; Tahir SK; Smith ML; Zhang H; Widomski D; Abraham VC; Xu N; Liu Z; Zhou L; DiGiammarino E; Lu X; Rudra-Ganguly N; Trela B; Morgan-Lappe SE
Cancer Res; 2021 Jun; 81(12):3402-3414. PubMed ID: 33687950
[TBL] [Abstract][Full Text] [Related]
3. The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells.
Legler K; Hauser C; Egberts JH; Willms A; Heneweer C; Boretius S; Röcken C; Glüer CC; Becker T; Kluge M; Hill O; Gieffers C; Fricke H; Kalthoff H; Lemke J; Trauzold A
Cell Death Dis; 2018 May; 9(5):445. PubMed ID: 29670075
[TBL] [Abstract][Full Text] [Related]
4. RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.
Brünker P; Wartha K; Friess T; Grau-Richards S; Waldhauer I; Koller CF; Weiser B; Majety M; Runza V; Niu H; Packman K; Feng N; Daouti S; Hosse RJ; Mössner E; Weber TG; Herting F; Scheuer W; Sade H; Shao C; Liu B; Wang P; Xu G; Vega-Harring S; Klein C; Bosslet K; Umaña P
Mol Cancer Ther; 2016 May; 15(5):946-57. PubMed ID: 27037412
[TBL] [Abstract][Full Text] [Related]
5. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
[TBL] [Abstract][Full Text] [Related]
6. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.
Motoki K; Mori E; Matsumoto A; Thomas M; Tomura T; Humphreys R; Albert V; Muto M; Yoshida H; Aoki M; Tamada T; Kuroki R; Yoshida H; Ishida I; Ware CF; Kataoka S
Clin Cancer Res; 2005 Apr; 11(8):3126-35. PubMed ID: 15837769
[TBL] [Abstract][Full Text] [Related]
7. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
[TBL] [Abstract][Full Text] [Related]
8. Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.
Milutinovic S; Kashyap AK; Yanagi T; Wimer C; Zhou S; O'Neil R; Kurtzman AL; Faynboym A; Xu L; Hannum CH; Diaz PW; Matsuzawa S; Horowitz M; Horowitz L; Bhatt RR; Reed JC
Mol Cancer Ther; 2016 Jan; 15(1):114-24. PubMed ID: 26516157
[TBL] [Abstract][Full Text] [Related]
9. A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors.
Zhang S; Zheng C; Zhu W; Xiong P; Zhou D; Huang C; Zheng D
Theranostics; 2019; 9(18):5412-5423. PubMed ID: 31410224
[TBL] [Abstract][Full Text] [Related]
10. An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.
Siegemund M; Seifert O; Zarani M; Džinić T; De Leo V; Göttsch D; Münkel S; Hutt M; Pfizenmaier K; Kontermann RE
MAbs; 2016 Jul; 8(5):879-91. PubMed ID: 27064440
[TBL] [Abstract][Full Text] [Related]
11. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
12. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
[TBL] [Abstract][Full Text] [Related]
13. Development of a bioassay as a measure of drozitumab-mediated apoptosis induced by soluble Fc gamma receptors.
Shim J; Huang A; Miller AS
J Immunol Methods; 2017 Sep; 448():26-33. PubMed ID: 28506821
[TBL] [Abstract][Full Text] [Related]
14. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.
Adams C; Totpal K; Lawrence D; Marsters S; Pitti R; Yee S; Ross S; Deforge L; Koeppen H; Sagolla M; Compaan D; Lowman H; Hymowitz S; Ashkenazi A
Cell Death Differ; 2008 Apr; 15(4):751-61. PubMed ID: 18219321
[TBL] [Abstract][Full Text] [Related]
15. IgG-single-chain TRAIL fusion proteins for tumour therapy.
Siegemund M; Schneider F; Hutt M; Seifert O; Müller I; Kulms D; Pfizenmaier K; Kontermann RE
Sci Rep; 2018 May; 8(1):7808. PubMed ID: 29773864
[TBL] [Abstract][Full Text] [Related]
16. Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.
Nagane M; Shimizu S; Mori E; Kataoka S; Shiokawa Y
Neuro Oncol; 2010 Jul; 12(7):687-700. PubMed ID: 20511188
[TBL] [Abstract][Full Text] [Related]
17. Identification of New DR5 Agonistic Nanobodies and Generation of Multivalent Nanobody Constructs for Cancer Treatment.
Sadeghnezhad G; Romão E; Bernedo-Navarro R; Massa S; Khajeh K; Muyldermans S; Hassania S
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569768
[TBL] [Abstract][Full Text] [Related]
18. Tetravalent antibody-scTRAIL fusion proteins with improved properties.
Seifert O; Plappert A; Fellermeier S; Siegemund M; Pfizenmaier K; Kontermann RE
Mol Cancer Ther; 2014 Jan; 13(1):101-11. PubMed ID: 24092811
[TBL] [Abstract][Full Text] [Related]
19. Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity.
Siegemund M; Pollak N; Seifert O; Wahl K; Hanak K; Vogel A; Nussler AK; Göttsch D; Münkel S; Bantel H; Kontermann RE; Pfizenmaier K
Cell Death Dis; 2012 Apr; 3(4):e295. PubMed ID: 22495350
[TBL] [Abstract][Full Text] [Related]
20. Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity.
Graves JD; Kordich JJ; Huang TH; Piasecki J; Bush TL; Sullivan T; Foltz IN; Chang W; Douangpanya H; Dang T; O'Neill JW; Mallari R; Zhao X; Branstetter DG; Rossi JM; Long AM; Huang X; Holland PM
Cancer Cell; 2014 Aug; 26(2):177-89. PubMed ID: 25043603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
